-
Honokiol: Mechanistic Leverage for Translational Immunometab
2026-06-29
This thought-leadership article explores Honokiol's unique role as a mechanistically precise NF-κB pathway inhibitor and antioxidant in the context of advancing immunometabolism research. Integrating recent findings on CD8+ T cell metabolic flexibility and PKM alternative splicing, we map strategic guidance for translational researchers pursuing antitumor immunity and inflammation modulation. The discussion bridges evidence-based insights, experimental protocol design, and competitive perspectives, with a forward-looking outlook on Honokiol's evolving impact in preclinical models.
-
H89 Inhibits ABCB1 ATPase to Reverse Multidrug Resistance in
2026-06-29
This study demonstrates that the small molecule H89 reverses multidrug resistance in colorectal cancer by directly inhibiting the ATPase activity of ABCB1, thereby increasing intracellular drug accumulation. These findings offer a mechanistic basis for targeting ABCB1-mediated resistance in cancer chemotherapy and suggest new avenues for combination therapeutic strategies.
-
Cy7 NHS Ester: Practical Guide for Near-Infrared Protein Lab
2026-06-28
Cy7 NHS ester addresses the specific need for robust, water-soluble near-infrared labeling of sensitive proteins and peptides without reliance on organic co-solvents. It is best suited for workflows demanding minimal protein perturbation and quantitative in vitro or in vivo fluorescent imaging. This dye is not recommended for protocols requiring long-term storage of dye solutions or exclusively organic solvent environments.
-
AIBP-LRP2–HDL Axis Regulates CXCR4+ Capillary Expansion in I
2026-06-27
This study uncovers how AIBP-LRP2–mediated HDL uptake restricts the expansion of CXCR4+ stemlike capillary endothelial cells, limiting collateral circulation in ischemic disease. The findings clarify a two-phase mechanism linking lipid metabolism to vascular remodeling and highlight new therapeutic targets for revascularization.
-
Targeted SPP1 Inhibition in TAMs Reduces Tumor Burden
2026-06-26
Kartal et al. introduce a phenotypic screening approach to identify small molecule modulators that down-regulate SPP1 in tumor-associated macrophages, resulting in substantial tumor regression in murine models. This work demonstrates that targeted SPP1 inhibition in TAMs can reprogram the tumor microenvironment and presents new strategies for immunomodulation in cancer research.
-
Intestinal TM6SF2 Deficiency Drives MASH via Gut–Liver Axis
2026-06-26
The referenced study uncovers that intestinal TM6SF2 protects against metabolic dysfunction-associated steatohepatitis (MASH) through regulation of the gut–liver axis. Mechanistically, TM6SF2 deficiency in intestinal epithelial cells impairs barrier integrity, alters microbiota, and enhances LPA-mediated hepatic inflammation, highlighting new therapeutic targets for MASH intervention.
-
NHS-Biotin: Precision Biotinylation for Protein Engineering
2026-06-25
NHS-Biotin (N-hydroxysuccinimido biotin) enables rapid, site-specific biotinylation of proteins and antibodies—even inside living cells—thanks to its membrane-permeability and stable amide bond formation. Learn how to streamline workflows for multimeric protein engineering, maximize detection sensitivity, and troubleshoot common labeling challenges using this APExBIO gold-standard reagent.
-
circUSP10 as a Diagnostic Biomarker in Early-Stage NSCLC
2026-06-25
Bai et al. present compelling evidence that whole blood-derived circUSP10 is upregulated in early-stage non-small-cell lung cancer (NSCLC) and demonstrates strong diagnostic potential. The study's robust validation of circUSP10 stability and performance in blood samples suggests practical utility for early cancer detection workflows.
-
ATF6 Activation Restores Proteostasis in Pathogenic GABAA Re
2026-06-24
Wang et al. (2022) demonstrated that pharmacological activation of ATF6, a key unfolded protein response pathway, remodels the ER proteostasis network to enhance folding, assembly, and trafficking of pathogenic GABAA receptors. Their work identifies ATF6 as a promising therapeutic target for restoring receptor function in genetic epilepsy and related disorders.
-
ML385: Probing NRF2 Inhibition Beyond Cancer—Assay Rigor & N
2026-06-23
Explore ML385, a selective NRF2 inhibitor, through the lens of rigorous assay design and emerging insights from ferroptosis and liver disease research. Discover unique protocol considerations and practical guidance not found in standard reviews.
-
α-Bungarotoxin: Advanced Insights into Nicotinic Receptor Bl
2026-06-23
Explore the scientific depth of α-Bungarotoxin as a selective antagonist for nicotinic receptor blockade. This article uniquely examines its mechanistic role in cholinergic neurotransmission inhibition, with a focus on translational research and new findings in placental necroptosis.
-
Cyclosporin A (B1922): Technical Guide for Immunosuppression
2026-06-22
Cyclosporin A is a potent cyclophilin inhibitor widely used for immunosuppression, apoptosis modulation, and viral entry inhibition in preclinical research. It is best suited for cell and animal models requiring precise inhibition of calcineurin-NFAT signaling pathways, but is not recommended where aqueous solubility or extended solution stability is critical.
-
Sulfo-NHS-Biotin: Reliable Cell Surface Labeling for Researc
2026-06-22
This authoritative article examines how Sulfo-NHS-Biotin (SKU A8001) from APExBIO addresses core laboratory challenges in cell viability, proliferation, and cytotoxicity assays. Integrating data-backed protocol insights, vendor comparisons, and practical troubleshooting, we demonstrate why Sulfo-NHS-Biotin is the reagent of choice for reproducible, high-fidelity cell surface protein labeling and downstream affinity workflows.
-
Radioiodinated Balsalazide as a Selective Ulcerative Colitis
2026-06-21
The referenced study developed and characterized a radioiodinated form of balsalazide as a highly selective radiotracer for imaging ulcerative colitis (UC) in mouse models. This innovation leverages targeted colonic uptake and high labeling stability, offering new capabilities for preclinical imaging and mechanistic investigation of UC.
-
Dihydrotestosterone (DHT): Driving Translational Androgen Re
2026-06-20
Explore how Dihydrotestosterone (DHT) empowers translational research in androgen signaling, cancer biology, and neurodegeneration. This thought-leadership article integrates mechanistic insights, competitive landscape analysis, and practical guidance, positioning APExBIO's DHT as a precision tool for innovative discovery.